Navigation Links
Pharsight Uses FDA Disease Model to Support Oncology Drug Development
Date:11/20/2007

Use of FDA Model in Non-Small Cell Lung Cancer Expected to Inform

Quantitative Predictions for Experimental Cancer Treatment

MOUNTAIN VIEW, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHRS), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that its Strategic Consulting Services Group is using a quantitative disease model developed by the Food and Drug Administration (FDA) for non-small cell lung cancer (NSCLC) to support an oncology drug development program sponsored by one of its clients, a global pharmaceutical company.

Pharsight scientists are using FDA's publicly available model in NSCLC to perform simulations of expected survival based on tumor shrinkage for an investigational drug in early clinical studies. Pharsight scientists also expect to refine these simulations with emerging data in new clinical studies to assist with key oncology development program decisions, including optimized dose selection and improved design of survival trials.

Pharsight's collective modeling and simulation experience in oncology includes longitudinal exposure-response modeling to inform labeling decisions and test dosing strategies, allometric projections, and work with novel mechanisms.

FDA has developed several quantitative drug-disease models based on the literature and clinical trial data from sponsor submissions for drug approval. FDA does not release proprietary source data from sponsors used to develop and validate the models, but the agency has underscored its commitment to publicly sharing and further testing the models that it has developed in important disease areas, including oncology. The NSCLC model was presented by FDA scientists at a January 2007 meeting, co-sponsored by FDA and the Drug Information Association (DIA), entitled "Sharing Knowledge to Improve Clinical Drug Development and Regulatory Decisions: Data/models of Diseases, Drugs, Placebo, Baseline, and Dropouts." Additional information can be found at http://www.diahome.org or requested from FDA at pharmacometrics@fda.hhs.gov.

"As outlined in FDA's Critical Path Initiative, model-based drug development offers an important approach to improving drug development knowledge management and decision-making," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "We are pleased that FDA has shared their NSCLC survival model with the public to describe prior knowledge in this area. With our unmatched collective modeling expertise, Pharsight scientists are uniquely positioned to help our clients build, adapt, and extend drug-disease models in their own development programs. Over the past three years, we have supported more than 30 oncology programs and modeling initiatives for industry clients, from pre-clinical to Phase III and covering critical issues in trial design, dose selection, and development strategy. We look forward to collaborating with our client to share feedback with FDA, and to contributing to ongoing industry discussions on opportunities for sharing drug-disease models to support quantitative decision-making in clinical development."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
9. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
10. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
11. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  Ethicon* today announced the completion of ... held medical device company that manufactures and markets ... treatment of Gastroesophageal Reflux Disease (GERD). This acquisition ... portfolio of minimally invasive options for patients suffering ... of the transaction have not been disclosed. ...
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... 2017  Drug diversion is a significant contributing ... overdoses. A new oral fluid monitoring test, announced ... reports more detailed and actionable information to clinicians ... therapy adherence, patient safety, and help to identify ... fluid Rx Evaluation (CORE) system is the first ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... new solution that enables organizations to easily reprint customer invoices, bills, statements and ... automates all of the steps needed to retrieve and print the documents and ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Monthly Monitoring Healthcare products at competitive pricing. Verisys through its ... Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted to be ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, ...                  , How will the new EU MDR language change the way ...
(Date:3/23/2017)... ... ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to heal ... creation of published author, Desiree M Webb, a registered nurse, minister of music, speaker, ... married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach ...
Breaking Medicine News(10 mins):